# DVA — DaVita · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** DVA  
**Sources:** 22  
**Published:** 2026-08-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-dva-davita-catalysts-narrative-risks-1423

---

## Point-in-time snapshot (as of ~Nov 15, 2026)

DVA last traded near $174.56 (up ~0.3% on Nov 14), with a market capitalization near $10.9–11.0 billion, a 52-week range of roughly $101–$247, and a trailing P/E near 13 [[12]](https://beststocks.com/stocks/dva/what-changed), [[16]](https://stockanalysis.com/stocks/dva/). Berkshire Hathaway remains the largest owner at ~41.2% of shares [[22]](https://en.m.wikipedia.org/wiki/DaVita), [[10]](https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/berkshire-s-davita-trim-comes-with-a-contractual-asterisk-while-october-s-rally-has-a-different/70440762). DaVita is a comprehensive kidney-care provider operating dialysis centers and lab services; as of Sept 30, 2026 it served ~298,100 patients at ~3,269 outpatient centers (2,671 in the U.S., 598 abroad) [[23]](https://investors.davita.com/). Roughly 68% of 2025 revenue came from Medicare/government programs, while commercial payers (~32% of revenue) generate nearly all of the profit [[22]](https://en.m.wikipedia.org/wiki/DaVita).

## Recent catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-dva-davita-catalysts-narrative-risks-1423 (free to sign up)._
